Abdominally Targeted Management Exercises for Crohn's Disease Patients (TAME-CD)
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 42
- 试验地点
- 1
- 主要终点
- Biomarker remission rate
研究概览
简要总结
The goal of this clinical trial is to learn if abdominally targeted exercises can assist to manage disease activity in Crohn disease (CD) patients.
The main questions it aims to answer are:
Does abdominally targeted exercises can improve the quality of life of CD patients.
Does abdominally targeted exercises positively influence clinical and biological responses in CD patients.
Researchers will compare performing sets of special physical exercises designed for CD patients, compared to a control set of exercises ("generic" physical activity) to see if exercises designed for CD can result in an improved quality of life, in CD patients suffering from mild to moderate disease activity.
Participants will:
- Perform physical exercises designed for CD or control set of exercises every day for 8 weeks.
- Visit the clinic once every 4 weeks for doctor visit, blood and stool test and filling out questionnaires.
详细描述
Inflammatory bowel diseases (IBD) are chronic relapsing diseases that carry considerable impact on patients' quality of life (QoL) including objective measures such as increased bowel movements and more subjective measures such as fatigue, stress and depression. While the pathogenesis of IBD is thought to result from a deregulated immune response towards microbial antigens in a genetically predisposed person, various associations of environmental factors and disease activity have been described. These include, but are not limited to diet, stress, physical activity, and microbial composition and function.
Mild to moderate physical activity, which by itself can be beneficial for patients who suffer from chronic disabling diseases such as IBD, is thought to have positive effects on health, general well-being and stress. The positive effects of physical activity can be mediated directly and/ or secondarily through its impact on other modifying factors such as sleep quality, bowel circadian rhythm, and perceived stress. In this regard, by reducing stress through physical activity, one can not only improve patients' QoL and reported outcomes (PROMs) such as sleep quality and stress reduction, which are an important measure by themselves; but also to improve subjective measures of the disease severity. Additionally, physical activity can impact the enteric microbiome, which can be beneficial in IBD patients.
It is currently not clear whether routine physical activity, performed by IBD patients, improves their symptoms, disease activity and quality of lives and if yes, which activity is mostly recommended.
In this study, the investigator intends to further examine whether these disease-specifically designed exercise sets can improve patients' perceived QoL and positively influence clinical and biological responses.
The hypothesize anticipates performing sets of special physical exercises designed for IBD patients, compared to a control set of exercises, can result in an improved QoL, in CD patients suffering from mild to moderate disease activity.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 60 Years(Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with no treatment or on constant medicinal therapy, expected to remain constant: mesalamine for at least 6 weeks, steroids at least 2 weeks (≤20mg prednisone or budesonide ≤6mg), immunomodulatory at least 12 weeks or biologics/ small molecules for at least 12 weeks therapy. Patients who initiate the study on steroids will remain on a constant dose throughout the study.
- •If patients stopped therapy prior to the study then they should be at least 2 weeks from stopping steroids or 5ASA, or 4 weeks from stopping small molecules, 8 weeks from stopping biologics, or 12 weeks from stopping thiopurines.
- •CD patients will be included if their symptoms score >4 and ≤15 on the HBI score
- •Fecal calprotectin>150ug/gr or evidence of an active disease per IUS defined as increased blood flow (modified Limberg score>0) or thickness of bowel wall>3mm
排除标准
- •Inability to commit for performing at least 10-15 minutes of exercise, 6 times a week.
- •Lack of availability or capability to use a computer/ internet.
- •Any proven current infection such as, fever, active abscess, Clostridioides difficile infection, positive stool culture, or parasite in patients with chronic diarrhea.
- •Inability to sign informed consent and/ or complete the study protocol.
- •Incompetent individuals who are unable to provide informed consent.
- •Planed pregnancy or pregnancy- up to 3 months post labor.
- •Subjects with chronic conditions such as active arthritis, cancer (within the previous 5 years, not including BCC, SCC), organ transplant subjects, advanced kidney or liver disease, or systemic inflammatory conditions other than IBD.
- •Patients who underwent surgery in the previous 3 months, had more than 1 surgery of intestinal resection, patients with ileostomy, pouch or patients with short bowel (small intestine<1.5 meter).
- •Patients with a significant abdominal wall hernia, unless received a written confirmation from a treating surgeon.
- •Active peri-anal disease (fistula, abscess, fissure), stricturing or penetrating disease
- •Active extra-intestinal manifestations (not excluded are- oral aphthae and peripheral arthralgia without arthritis)
- •Patients on total parenteral nutrition (TPN) or on exclusive enteral nutrition (EEN).
- •Probiotics or antibiotics in the 15 days prior to enrollment or during the study period.
研究组 & 干预措施
Abdominally targeted exercises
The interventional exercise regimen will include specific abdominally targeted exercises postulated to increase blood flow to the intestine and decrease inflammation. Patients will be asked to perform the exercises 6 days every week. Patients will be asked to complete 3 different videos repeatedly, one video per day, as many days a week as possible.
干预措施: Abdominally targeted exercises (Other)
Generally recommended exercises
The control arm will practice generally recommended exercises, without particular attention to the abdomen. Patients will be asked to perform the exercises 6 days every week. Patients will be asked to complete 3 different videos repeatedly, one video per day, as many days a week as possible.
干预措施: General exercises (Other)
结局指标
主要结局
Biomarker remission rate
时间窗: From enrollment to the end of treatment at 8 weeks
biomarker remission as defined by calprotectin \<150 μg/g. Lower levels indicate better outcome
Change from Baseline in mean values of IBDQ
时间窗: From enrollment to the end of treatment at 8 weeks
To assess the differences in patients' perceived QoL according to patients reported outcomes questionnaires: Inflammatory Bowel Disease Questionnaire (IBDQ)
Clinical response rate
时间窗: From enrollment to the end of treatment at 8 weeks
Clinical response rate will be assessed by using a clinical activity index, Harvey-Bradshaw index (HBI), and defined by a decrease of ≥3 points. A greater decrease is regarded as a better response.
Clinical remission rate
时间窗: From enrollment to the end of treatment at 8 weeks
Clinical remission rate will be assessed by using a clinical activity index, HBI defined by achieving HBI\<5. Lower scores indicate lower disease activity and severity.
Change from Baseline in mean values of PROMIS-29 scores
时间窗: From enrollment to the end of treatment at 8 weeks
To assess the differences in patients' perceived QoL according to patients reported outcomes questionnaires: Patient-Reported Outcomes Measurement Information System (PROMIS-29)
次要结局
- IUS remission rate(End of treatment at 8 weeks)
- Clinical remission rate(From enrollment to 4 weeks)
- Biomarker response rate(From enrollment to the end of treatment at 8 weeks)
- Clinical response rate(From enrollment to 4 weeks)
- Change from Baseline in mean values of IBDQ(From enrollment to 4 weeks)
- Change from Baseline in mean values of PROMIS-29 scores(From enrollment to 4 weeks)
研究者
Shmuel Kivity, MD
Professor
Tel-Aviv Sourasky Medical Center
